Literature DB >> 25576512

Lamellar macular hole after intravitreal ocriplasmin injection.

Ross Bronson Chod1, Clifford Goodrich1, Sandeep Saxena2, Levent Akduman1.   

Abstract

Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25576512      PMCID： PMC4289753          DOI： 10.1136/bcr-2014-207810

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  12 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  Idiopathic senile macular hole. Its early stages and pathogenesis.

Authors:  J D Gass
Journal:  Arch Ophthalmol       Date:  1988-05

3.  Three-dimensional spectral domain optical coherence tomography in vitreomacular traction.

Authors:  Sandeep Saxena; Carsten H Meyer; Levent Akduman
Journal:  BMJ Case Rep       Date:  2014-06-17

4.  Age-related changes in human vitreous structure.

Authors:  J Sebag
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

5.  Surgical excision of the attached posterior hyaloid.

Authors:  D P Han; G W Abrams; T M Aaberg
Journal:  Arch Ophthalmol       Date:  1988-07

6.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.

Authors:  L A Liotta; R H Goldfarb; R Brundage; G P Siegal; V Terranova; S Garbisa
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

7.  Tomographic features of a lamellar macular hole formation and a lamellar hole that progressed to a full-thickness macular hole.

Authors:  H Takahashi; S Kishi
Journal:  Am J Ophthalmol       Date:  2000-11       Impact factor: 5.258

8.  A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy.

Authors:  Matthew S Benz; Kirk H Packo; Victor Gonzalez; Stephen Pakola; Donna Bezner; Julia A Haller; Steven D Schwartz
Journal:  Ophthalmology       Date:  2010-04       Impact factor: 12.079

9.  Posterior vitreous detachment induced by microplasmin.

Authors:  Arnd Gandorfer; Matthias Rohleder; Charanjit Sethi; Dominik Eckle; Ulrich Welge-Lüssen; Anselm Kampik; Philip Luthert; David Charteris
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

10.  Retinal breaks due to intravitreal ocriplasmin.

Authors:  Ruwan A Silva; Darius M Moshfeghi; Theodore Leng
Journal:  Clin Ophthalmol       Date:  2014-08-25
View more
  3 in total

1.  Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.

Authors:  Irini Chatziralli; George Theodossiadis; Efstratios Parikakis; Ioannis Datseris; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

Review 2.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

Review 3.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.